Category
Bpc 157
3 articles
compounding pharmacyTGA
Compounding Pharmacy Regulation in Australia: The TGA, GLP-1 Shortages, and the Policy Tension
How TGA Section 19A, compounded semaglutide and tirzepatide during national shortages, the BPC-157 Schedule 4 reclassification, and Pharmacy Board notifications have turned compounding into a national policy issue balancing patient access against sterile-injectable safety.
8 May 202614 min read
TGApeptides
TGA Regulation of Peptides in Australia: What Patients and Clinicians Need to Know
Australia's Therapeutic Goods Administration classifies peptides under a complex scheduling framework. This guide explains TGA peptide schedules, the March 2025 BPC-157 rescheduling, compounding pharmacy access, and what 'research use' means legally.
15 Apr 202631 min read
BPC-157TGA
BPC-157 Schedule 4 in Australia: What the TGA Rescheduling Means and What Comes Next
A detailed policy and science analysis of Australia's TGA decision to reschedule BPC-157 to Schedule 4 in June 2024 — regulatory rationale, clinical implications, and the research evidence for this peptide.
5 Apr 202627 min read